ABSTRACT
This chapter contributes to the scholarly literature in crisis communication by emphasizing on the media coverage of the first three months of the Covid-19 pandemic in Canadian newspapers. Indeed, described as a health, social, and economic crisis, Covid-19 swiftly plunged the world into a state of crisis. Media coverage of the pandemic contributes to crisis communication, by attempting to make sense of the new coronavirus and its many impacts on global order. Thanks to an innovative methodological approach, we analyzed the journalistic coverage through a simultaneous tripartite process of staging the protagonists (Who?), selecting different facets of social reality (What?), and positioning with respect to professional ideals (How?). © Springer Nature Switzerland AG 2023. All rights reserved.
ABSTRACT
PLANS A, B, AND C It's important to have your plan A but also a plan B or even a plan C. As an example, you may have envisioned lots of travel, and then along came COVID, or a new partner, or health problems that make travel less likely. Amenities in these retirement communities include gyms, restaurants, golf courses, tennis courts, swimming pools, and interesting lectures\classes that make your retirement pleasurable. [...]you might want to improve your gardening skills, landscape your yard, paint the fence, clean the garage, and sit and watch the sunset. Look into courses at a local community college or university;many higher education centers allow individuals to take non-credit classes at a low cost.
ABSTRACT
purpose was to explore the symptoms and supportive care needs experienced by patients in remission after tisa-cel or liso-cel chimeric antigen receptor (CAR) T-cell therapy. Though CAR T-cell therapy is expanding in application to various types of cancers, little information is available about the patient symptom experience, symptom management, and supportive care needs, especially three months or more after therapy. This was a qualitative study. Participants were recruited from a comprehensive medical center if they met the following criteria: > 18 years of age, English-speaking, history of B-cell lymphoma, received tisa-cel or liso-cel between 3 months to one year, and currently in remission. Data collection utilized semi-structured telephone interviews that were audio-recorded and transcribed. Two independent coders used NVivo Software to code transcripts. Content analysis was used to analyze the interview data. Data analysis is ongoing. Ten patients who received tisa-cel (n=7) or liso-cel (n=3) for B-cell lymphoma participated in the study. The average time since infusion was 187.5 days, ranging from 113 to 261 days. Participant mean age was 64.5 years. Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) toxicity grades were gathered from medical chart review: CRS grade 0 (n=3), CRS grade 1 (n=5), CRS grade 2 (n=i), CRS grade 3 (n=i), and ICANS grade 0 (n=io). The most commonly described symptoms included fatigue, weakness, joint pain, and memory-issues. Most participants reported they were self-sufficient in their activities of daily living. However, some participants expressed physical limitations and social isolation, due to compromised immune systems and concerns related to COVID -19. Participants described the perceived burden for their caregivers. Supportive care needs included cooking meals and grocery shopping. Though our study focused on patients in remission to avoid confounding with ongoing disease or treatment, patients still reported symptoms and side effects. Notably, some participants experience symptoms (e.g., neuropathy) from prior chemotherapy treatments. Participants expressed being unsure of whether ongoing symptoms were related to prior treatments or from the CAR T-cell therapy. Oncology nurses should continue to assess symptoms among adult CAR T-cell patients in remission and offer supportive care as needed. Future research may determine what patients are more at risk of developing long-term symptoms, to describe symptom trajectory, and develop targeted interventions to reduce symptom burden and meet supportive care needs.
ABSTRACT
Afra et al present several facts about the effectiveness of tocilizumab for patients with COVID-19. Among other things, tocilizumab is an immunomodulatory drug that blocks the activity of interleukin-6 (IL-6). Many patients with severe coronavirus disease 2019 have immune misfiring characterized by a defective interferon response followed by elevated inflammatory cytokines, notably IL-6. Tocilizumab is a monoclonal IL-6 receptor antibody that is approved for use in inflammatory conditions.